Quizartinib Dihydrochloride
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia With Gene Mutations
Conditions
Acute Myeloid Leukemia With Gene Mutations
Trial Timeline
— → —
NCT ID
NCT03746912About Quizartinib Dihydrochloride
Quizartinib Dihydrochloride is a pre-clinical stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia With Gene Mutations. The current trial status is completed. This product is registered under clinical trial identifier NCT03746912. Target conditions include Acute Myeloid Leukemia With Gene Mutations.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03746912 | Pre-clinical | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia With Gene Mutations